Latent fingermark development on fired and unfired brass ammunition under controlled and blind conditions.

There has been growing interest in the Foster+Freeman RECOVER® Latent Fingerprint Technology system to develop fingermarks from fired ammunition. Over a six-month period, 1540 fingermarks were deposited on brass.223 ammunition, the majority of which were then fired after different time intervals. Samples were subjected to a cleaning protocol and/or processed with disulfur dinitride, cyanoacrylate/Brilliant Yellow 40, and/or vacuum metal deposition. Overall, 121 out of 1304 (9.3%) of natural fingermarks deposited were deemed identifiable post-firing and processing. This translated to 102 out of 652 (15.6%) of fired cartridges having identifiable fingermarks. A pseudo-operational study, which involved processing 1000 fired brass ammunition of various caliber using disulfur dinitride with and without a cleaning protocol, was conducted; only 18 (1.8%) comparable fingermarks were developed. This study demonstrates the need for more robust research involving this challenging substrate and novel technology, with which several issues were identified.

Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study.

BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not routinely performed before primaquine treatment in most Plasmodium vivax endemic areas, despite the risk of primaquine-associated hemolysis. This is due to the operational challenges associated with pragmatic G6PD testing and as such needs to be addressed. METHODS AND FINDINGS: This mixed-methods operational study was aimed at implementing the quantitative point-of-care StandardTM G6PD (SD Biosensor, Korea) screening test in malaria treatment units (MTUs) in the municipalities of Rio Preto da Eva and Mâncio Lima, in the Brazilian Amazon, between mid-January 2020 and December 2020. In total, 1286 P. vivax cases were treated based on the Standard G6PD test: 1230 had activity equal to or greater than 4.0 U/g Hb, and 56 less than 4.0 U/g Hb. No G6PD deficient (G6PDd) genotypes were found in 96 samples from the 1230, and only 21 of the 56 G6PDd cases had confirmed G6PDd genotypes. Evaluations were conducted on the proficiency of health care professionals (HCPs) training to perform the test, the reliability of testing performed in the field, and the perceptions of HCPs and patients about the implementation. Post-training proficiency was 73.4% after a 4-hour training session. This study revealed that locations with lower malaria caseloads will need regular refresher training. The test was well accepted by both HCPs and patients. Signs and symptoms of hemolysis were not always associated with malaria treatment drugs by HCPs and patients. INTERPRETATION: Point-of-care quantitative G6PD testing can be performed at MTUs in the Brazilian Amazon to inform treatment decisions with primaquine. Limitations related to technical and cultural aspects need to be addressed further when expanding screening to larger areas.